Originally published by our sister publication Clinical Oncology News
By Kate O’Rourke
In patients with recurrent platinum-resistant/-refractory ovarian cancer, treatment with botensilimab (Agenus), a novel multifunctional CTLA-4 (cytotoxic T-lymphocyte–associated antigen 4) antibody, plus balstilimab (Agenus), a PD-1 (programmed death-1) antibody, yielded a 33% overall response rate (ORR). Results from the expanded phase 1b trial were presented in an oral plenary session at the